The Heart Protection Study: high-risk patients benefit from statins, regardless of LDL-C level.
The landmark Heart Protection Study (Lancet 2002; 360:7-22) found benefit in treating subjects at high risk of a coronary event with simvastatin 40 mg daily, regardless of baseline low-density lipoprotein cholesterol level and in all subgroups, including women and the elderly. The study found no benefit of simvastatin therapy in preventing noncardiac events (eg, dementia, osteoporotic fractures), and no negative effects, such as an increase in cancer, respiratory disease, or suicide.
Gurm
Hitinder S
HS
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
Hoogwerf
Byron
B
D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D019821:Simvastatin / Q000627:therapeutic use; D016896:Treatment Outcome
D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin